ArticleJournal of virology2025
The HCMV tegument protein UL88 degrades MyD88 and reduces innate immune activation.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Multi-Omics Analysis Reveals an HCMV-Associated Late-Gene Signature Associated with Poor Survival in Pediatric Group 3 Medulloblastoma.Biomedicines · 2026Article
- High human cytomegalovirus antigen expression in pediatric medulloblastoma tissue is associated with poor event-free survival.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The human cytomegalovirus (HCMV) encodes the tegument protein UL88, which supports virus spread by mediating the degradation of the innate immune signaling adapter protein, myeloid differentiation primary response 88 (MyD88). MyD88 transduces signals in multiple innate immune pathways, including acting downstream of pattern recognition receptors and IL-1 cytokine family members. MyD88 is rapidly and robustly upregulated following exposure to HCMV, irrespective of viral gene expression and, even after infection, primarily within uninfected cells in a culture. However, UL88 was required to downregulate cellular MyD88 protein levels as HCMV spread through a culture. The N-terminal 181 amino acids of UL88 were required to associate with and downregulate MyD88 protein. MyD88 expression significantly suppressed virus spread by triggering the production of a heat-labile soluble factor. This factor was produced between ~3 and 6 days after initial infection and did not increase the expression of well-characterized interferon-stimulated genes (ISGs). Indeed, increased MyD88 expression downregulated the expression of almost all ISGs examined. UL88 overexpression suppressed IL-1β-induced NF-κB activation within a cell. UL88 also suppressed virus-induced translocation of NF-κB to the nucleus of uninfected neighboring cells in an infected monolayer. Furthermore, UL88 overexpression was required for effective HCMV spread following transfer of the virus from monocytes to a fibroblast monolayer. These data indicate that UL88 is a novel antagonist of the immune response that acts to enhance the natural spread of HCMV by targeting MyD88 and provides vital insight into the innate immune responses that can control HCMV spread.IMPORTANCEThe significant role of many viral genes encoded by HCMV that are not essential for replication in cell culture is often overlooked. Our study reveals the importance of UL88 for regulating the innate immune response by showing evidence for interaction with and downregulation of MyD88 protein. The UL88-dependent regulation of MyD88 is physiologically relevant, as infection is enhanced in the absence of MyD88, and spread from myeloid cells to fibroblasts is blunted in the absence of UL88. These results highlight yet another important interaction between HCMV and the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.